Methadone treatment for HIV prevention- Feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: A Retrospective cohort study

Clinical Infectious Diseases

Volumn 59, Issue 5, 2014, Pages 735-742

  Lambdin, Barrot H ^a,c   Masao, Frank ^b   Chang, Olivia ^c   Kaduri, Pamela ^b   Mbwambo, Jessie ^b   Magimba, Ayoub ^d   Sabuni, Norman ^d   Bruce, R Douglas ^c,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c Pangaea Global AIDS Foundation   (United States)

^d MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Implementation science; Methadone; People who inject drugs; Sub Saharan Africa

Indexed keywords

METHADONE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METHADONE TREATMENT; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEXUAL ABUSE; SURVIVAL; TANZANIA; EPIDEMIOLOGY; HIV INFECTIONS; INCIDENCE; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; YOUNG ADULT;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDIES; TANZANIA; YOUNG ADULT;

EID: 84907405144     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu382     Document Type: Article

References (47)

1. Ross MW, McCurdy SA, Kilonzo GP, Williams ML, Leshabari MT. Drug use careers and blood-borne pathogen risk behavior in male and female Tanzanian heroin injectors. Am J Trop Med Hyg 2008; 79:338-43.
2. United Nations on Drugs and Crime. The global Afghan opium trade: a threat assessment. Available at: http://www.unodc.org/documents/data-and- analysis/Studies/Global-Afghan-Opium-Trade-2011-web.pdf. Accessed 1 March 2013.
3. McCurdy SA, Ross MW, Kilonzo GP, Leshabari MT, Williams ML. HIV/AIDS and injection drug use in the neighborhoods of Dar es Salaam, Tanzania. Drug Alcohol Depend 2006; 82(suppl 1):S23-27. (Pubitemid 43850173)
4. McCurdy SA, Williams ML, Kilonzo GP, Ross MW, Leshabari MT. Heroin and HIV risk in Dar es Salaam, Tanzania: youth hangouts, mageto and injecting practices. AIDS Care 2005; 17(suppl 1):S65-76. (Pubitemid 40979478)
5. Tanzania Drug Control Commission. The national strategic framework for HIV/AIDS prevention for injecting drug users (2011-2015). Dar es Salaam, Tanzania October 2010:1-41.
6. Williams ML, McCurdy SA, Bowen AM, et al. HIV seroprevalence in a sample of Tanzanian intravenous drug users. AIDS Educ Prev 2009; 21:474-83.
7. Williams ML, McCurdy SA, Atkinson JS, Kilonzo GP, Leshabari MT, Ross MW. Differences in HIV risk behaviors by gender in a sample of Tanzanian injection drug users. AIDS Behav 2007; 11:137-44. (Pubitemid 46147360)
8. Tanzania Commission for AIDS, Zanzibar AIDS Commission, National Bureau of Statistics, Office of Chief Government Statistician Zanzibar, ICF International. Third Tanzania HIV/AIDS and malaria indicator survey 2011-2012. 2013. Available at: http://www.tacaids.go.tz/index.php?option=com- content&view=article&id=138:about-hiv-and-aids&catid=31: hiv-and-aids-information-&Itemid=158. Accessed 12 August 2013.
9. Nyandindi C, Mbwambo J, McCurdy S, Lambdin B, Copenhaver M, Bruce R. Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni Municipality in Dar es Salaam, Tanzania. In: College on Problems of Drug Dependence, San Diego, CA, 2013.
10. Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy 2010; 21:122-4.
11. Ball JC, Ross A, Dole VP. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. Vol xiv. New York: Springer-Verlag, 1991.
12. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6:1049-56. (Pubitemid 23239778)
13. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1-171, iii-iv.
14. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999; 13:1807-18. (Pubitemid 29509539)
15. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010; 105:907-13.
16. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS 2005; 19:837-9. (Pubitemid 40834758)
17. McCurdy SA, Ross MW, Williams ML, Kilonzo GP, Leshabari MT. Flashblood: blood sharing among female injecting drug users in Tanzania. Addiction 2010; 105:1062-70.
18. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th ed. Text revision (DSM-IV-TR).Washington, DC: APA, 2000. Available at: http://buprenorphine.samhsa.gov/Bup-Guidelines.pdf. Accessed 15 August 2013.
19. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment improvement protocol (TIP) series, No. 40. Rockville, MD: SAMHA, 2004. Available at: http://www.ncbi.nlm.nih.gov/books/NBK64247/. Accessed 15 August 2013.
20. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins symptom checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatr 1974; 7:79-110.
21. Lee B, Kaaya SF, Mbwambo JK, Smith-Fawzi MC, Leshabari MT. Detecting depressive disorder with the Hopkins Symptom Checklist-25 in Tanzania. Int J Soc Psychiatry 2008; 54:7-20.
22. Kaaya SF, Fawzi MCS, Mbwambo JK, Lee B, Msamanga GI, Fawzi W. Validity of the Hopkins Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania. Acta Psychiatrica Scandinavica 2002; 106:9-19. (Pubitemid 34828143)
23. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2:CD002207.
24. Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62:255-64. (Pubitemid 32276073)
25. Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 2008; 11:641-53. (Pubitemid 351931822)
26. Liu E, Liang T, Shen L, et al. Correlates of methadone client retention: a prospective cohort study in Guizhou province, China. Int J Drug Policy 2009; 20:304-8.
27. Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abuse Treat 2012; 42:239-46.
28. Anderson JF, Warren LD. Client retention in the British Columbia methadone program, 1996-1999. Can J Public Health 2004; 95:104-9. (Pubitemid 38578669)
29. Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend 2004; 74:177-85. (Pubitemid 38501691)
30. Magura S, Nwakeze PC, Demsky SY. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998; 93:51-60. (Pubitemid 28045138)
31. Beynon CM, McMinn AM, Marr AJ. Factors predicting drop out from, and retention in, specialist drug treatment services: a case control study in the north west of England. BMC Public Health 2008; 8:1-11.
32. Encrenaz G, Rondeau V, Messiah A, Auriacombe M. Examining the influence of drop-outs in a follow-up of maintained opiate users. Drug Alcohol Depend 2005; 79:303-10. (Pubitemid 41127158)
33. Gryczynski J, Kinlock TW, Kelly SM, O'Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus 2012; 33:30-9.
34. Craig RJ, Rogalski C, Veltri D. Predicting treatment dropouts from a drug abuse rehabilitation program. Int J Addict 1982; 17:641-53. (Pubitemid 12081013)
35. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d 'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-82. (Pubitemid 351563837)
36. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006; 20:41-8. (Pubitemid 41818113)
37. Lambdin B, Bruce D, Chang O, Masao F, Nyandindi C, Ivo Y. Program and patient characteristics associated with people who inject drugs defaulting from medication assisted treatment in Dar es Salaam, Tanzania. In: International AIDS Society, Kuala Lumpur, Malaysia, 2013.
38. Lambdin BH, Bruce RD, Chang O, et al. Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania. PLoS One 2013; 8:e67062.
39. Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse 2009; 35:28-33.
40. Wang PW, Wu HC, Yen CN, et al. Change in quality of life and its predictors in heroin users receiving methadone maintenance treatment in Taiwan: an 18-month follow-up study. Am J Drug Alcohol Abuse 2012; 38:213-9.
41. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) 2002; 161:202-12. (Pubitemid 34492665)
42. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005; 100:1496-509. (Pubitemid 41442319)
43. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000-5. (Pubitemid 29143891)
44. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend 2011; 113:192-9.
45. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
46. Perlis TE, Des Jarlais DC, Friedman SR, Arasteh K, Turner CF. Audio-computerized self-interviewing versus face-to-face interviewing for research data collection at drug abuse treatment programs. Addiction 2004; 99:1-7.
47. Koepsell TD, Weiss NS. Epidemiologic methods: studying the occurrence of illness. New York: Oxford University Press, 2003.